Data from Phase 2 Trial of Prurisol for Psoriasis to be Unblinded Next Week, Top-Line Results to Follow

BEVERLY, MA–(Marketwired – May 11, 2016) - Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be “unblinded” next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed.

Separately in Cellceutix’s dermatology pipeline, the Company last month reactivated a request for a Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) to discuss initiating clinical research of Brilacidin, Cellceutix’s lead defensin mimetic, for the treatment of the inflammatory skin condition hidradenitis suppurativa. Cellceutix previously filed the request, ultimately electing to hold off on clinical studies of Brilacidin for dermatological uses until several other clinical trials sponsored by the Company were completed or neared completion. Cellceutix anticipates the meeting to transpire in June 2016 and will be submitting a Briefing Book to the FDA on the planned trial one month prior to the meeting.

More on the Phase 2 trial of Prurisol can be found on